MolecuLight, a Toronto, Canada-based point-of-care fluorescence imaging company, raised $11.7M in Series C funding.
The round was led by Export Development Canada (EDC), Prosegur, and Azahar. Existing investors also participated.
The company intends to use the funds to reach more patients by providing clinicians with tools to identify and quantify bacteria that impair wound healing, in turn improving patient outcomes.
Led by CEO Anil Amlani, MolecuLight is a point-of-care fluorescence imaging company whose devices empower healthcare providers to detect elevated levels of bacteria in wounds, surgical sites, and other injuries. By optimizing treatment plans, the technology helps users accelerate healing and reduce the risk of complications. The multi-modal device combines bacterial detection, wound measurement, and imaging capabilities into a single tool, streamlining workflows and improving documentation accuracy. Integrating with electronic medical records, MolecuLight empowers clinicians to deliver the highest standard of care while optimizing their workflow.
FinSMEs
15/08/2024